NSCLC, like other tumors with high TMB, have been shown to possess a significant number of TSAs arising from various somatic mutations, including driver genes like tumor protein 53 (TP53), Kristen Rat sarcoma viral oncogene homolog (KRAS), cyclin-dependent kinase inhibitor 2A (CDKN2A), AT-Rich Interaction Domain 1A (ARID1A), Neurogenic locus notch homolog protein 1 (NOTCH1), myelocytomatosis oncogene (MYC), SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4 (SMARCA4), and retinoblastoma 1 (RB1) (204, 205). This evidence concerns the gene CDKN2A and non-small cell lung carcinoma.